The purpose of the study is to see if empasiprubart can help improve the ability to perform daily activities compared to placebo. The study will also look at how safe the medication is and how well it is tolerated by people with this nerve condition. Researchers want to understand if this treatment can help reduce disability and improve quality of life for people living with this condition.

The study is divided into two parts and will last up to about two years for each person who takes part. During the study, empasiprubart will be given through a needle into a vein, which is called an infusion. People taking part will have regular visits where doctors will check their muscle strength, ability to perform daily tasks, grip strength, and overall well-being. The study will also measure various safety aspects including blood tests, heart function tests, and any side effects that may occur. Throughout the study, researchers will collect blood samples to measure the levels of the medication in the body and to see how the immune system responds to the treatment.

The purpose of this study is to show whether empasiprubart works better than human normal immunoglobulin in improving the ability to perform daily activities in adults with this nerve condition. During the study, participants will be randomly assigned to receive either empasiprubart or human normal immunoglobulin through a vein. The study uses a double-dummy design, which means that all participants will receive two infusions to ensure that neither the participants nor the doctors know which treatment is being given. The main assessment will happen at week 24, when doctors will measure changes in functional ability using a scoring system that evaluates arm and leg function.

Throughout the study, various measurements will be taken to assess how well participants can perform daily tasks, their muscle strength, their walking ability, and their overall quality of life. Grip strength will be measured regularly, and participants will complete questionnaires about their disability, fatigue, pain, and general health status. Blood samples will be taken to measure drug levels and to check for any immune responses to the treatment. Safety will be monitored by tracking any unwanted effects, changes in laboratory tests, heart rhythm recordings, and vital signs. The study will also look at how the treatments affect specific proteins in the blood that are involved in the immune response and nerve damage.

People taking part in this study will already be receiving treatment for their condition with either steroid medications taken by mouth or immunoglobulin therapy given through a vein or under the skin. During the study, participants will be checked regularly to see if their symptoms worsen or stay stable. The study will look at different measures of how well people can perform daily activities and how strong their muscles are, including grip strength in the dominant hand and overall muscle strength.

The study will last for several years and will involve multiple visits where various assessments will be done. The main focus will be on measuring whether people remain free from worsening of their condition over a period of 24 weeks. Other measurements will include changes in the ability to perform daily tasks, hand grip strength, and overall muscle strength at the same time point.

The study involves two main parts. In the first part, all participants receive DNTH103 to check if they respond to the treatment. In the second part, participants who showed improvement will be randomly assigned to continue receiving either DNTH103 or placebo. The treatment period lasts several months, during which participants will receive regular injections and undergo various assessments to monitor their condition.

Throughout the study, doctors will measure participants’ muscle strength, ability to perform daily activities, and overall quality of life. They will also monitor for any side effects and check how the medication works in the body. The maximum daily dose of DNTH103 will be 1200 mg, and participants may receive treatment for up to 172 days.

The purpose of this research is to compare how these medications work in the body when given under the skin (through subcutaneous injection). The study will use various medical devices including an infusion pump and special needle sets to deliver the medication. Participants will receive treatment for approximately 27 weeks.

During the study, participants will receive either TAK-881 or HyQvia through regular injections under the skin. The medication will be given using specialized equipment to ensure proper delivery. Blood samples will be collected to measure the levels of the medication in the body over time.

Participants in this study will receive riliprubart through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants over an extended period to observe any side effects or adverse events that may occur. Additionally, the study will track the percentage of participants who remain free from relapses and those who show improvement in their condition. Changes in disability scores, grip strength, and muscle strength will also be measured to evaluate the effectiveness of the treatment.

The study is designed to provide valuable information about the long-term use of riliprubart in managing CIDP. By participating in this study, researchers aim to gather data that could help improve treatment options for individuals living with this chronic condition. The study is expected to continue until 2029, allowing for comprehensive observation and analysis of the treatment’s impact over time.

Participants in the study will receive NVG-2089 over a period of time, and researchers will monitor them to observe any side effects or improvements in their condition. The study will involve regular check-ups and assessments to ensure the well-being of the participants and to gather data on how the treatment affects their symptoms. The study aims to provide valuable information on the potential benefits and risks of using NVG-2089 for treating CIDP.

Throughout the study, participants will be closely observed for any changes in their health, including any adverse reactions to the treatment. The study will also track improvements in symptoms such as muscle strength and overall physical ability. This research is important for understanding how NVG-2089 can be used to help people with CIDP and to determine its effectiveness and safety as a treatment option.

The purpose of this study is to evaluate how safe and well-tolerated Batoclimab is over an extended period. Participants in the study will receive regular injections of Batoclimab and will be monitored for any side effects or changes in their condition. The study aims to gather information on how participants respond to the treatment over time.

Participants will be involved in the study for up to 52 weeks, during which they will receive Batoclimab injections and attend regular check-ups to assess their health and any potential side effects. The study will help determine if Batoclimab is a safe and effective long-term treatment option for people with CIDP.

The purpose of the study is to determine if adding Rituximab to a limited period of another treatment called IVIg (intravenous immunoglobulin) can lead to long-term remission of CIDP. Remission means that the symptoms of the disease are reduced or disappear for a period of time. The study aims to see if this combination can help patients stop needing regular IVIg infusions, which can be inconvenient and costly.

Participants in the study will receive Rituximab and will be monitored over a period of time to see if they achieve remission at 52 weeks after starting the treatment. The study will also check if the treatment remains effective at 104 weeks. The goal is to find out if Rituximab can help patients with CIDP maintain stability without needing additional treatments. The study is expected to continue until 2028.

The purpose of the study is to evaluate how effective Batoclimab is in maintaining a clinical response in people with CIDP who are already receiving treatments like immune globulin or plasma exchange. Participants will be randomly assigned to receive either Batoclimab or a placebo. The study will be conducted over a period of time, and participants will receive regular injections. The trial aims to see if Batoclimab can help prevent relapses, which are periods when symptoms worsen.

Throughout the study, participants will be monitored to assess their response to the treatment. This will include checking for any changes in their condition and measuring their strength and ability to perform daily activities. The study will help determine if Batoclimab is a safe and effective treatment option for people with CIDP.

Participants in the study will receive either nipocalimab or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over several stages, and participants will be monitored for any changes in their condition, as well as any side effects they may experience.

The trial will involve regular assessments to track the progression of CIDP symptoms and the overall health of the participants. These assessments will include checking muscle strength, grip strength, and other physical abilities. The study aims to provide valuable information on whether nipocalimab can be a beneficial treatment option for people living with CIDP.

Participants in the study will receive either riliprubart or a placebo, which is a substance with no active medication. The study will be conducted over a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment. The study aims to assess how well riliprubart works in improving the symptoms of CIDP and its long-term effects on the condition.

Throughout the study, participants will be closely monitored for any changes in their condition and any side effects they may experience. The study will use various measures to evaluate the effectiveness of riliprubart, including changes in disability scores and grip strength. The goal is to determine if riliprubart can provide a meaningful improvement for people with CIDP who have not responded to other treatments.

The purpose of the study is to evaluate how effective, safe, and tolerable riliprubart is for adults with CIDP. The study is divided into two parts. In the first part, the focus is on how well riliprubart works in three groups of CIDP patients: those who are currently receiving standard treatments, those who do not respond well to standard treatments, and those who have not yet received standard treatments. The second part of the study looks at the long-term safety and tolerability of riliprubart in these patients.

Participants in the study will receive riliprubart and will be monitored for any changes in their condition and any side effects they may experience. The study will also track the number of participants who respond to the treatment and those who experience any adverse events. This research aims to provide more information about riliprubart as a potential treatment option for people living with CIDP.

The purpose of the study is to evaluate how well riliprubart works in treating CIDP compared to continuing with IVIg. Participants in the study will receive either riliprubart or IVIg, and some may receive a placebo, which looks like the treatment but does not contain the active substance. The study will monitor participants over a period to assess their response to the treatment, focusing on improvements in their condition and any side effects they may experience.

Throughout the study, participants will undergo regular assessments to track changes in their symptoms and overall health. These assessments will help determine the effectiveness of riliprubart in managing CIDP symptoms and its long-term benefits. The study aims to provide valuable information on whether riliprubart can be a viable alternative to the current standard treatment with IVIg for people living with CIDP.

Participants in the study will receive efgartigimod injections and will be monitored for any side effects or changes in their condition. The study will also include a comparison with a placebo to evaluate the treatment’s effectiveness. Throughout the study, various health assessments will be conducted to track the participants’ progress and any potential improvements in their symptoms.

The study is designed to gather information on how efgartigimod affects patients with CIDP over time, including any changes in their ability to perform daily activities and their overall quality of life. The goal is to determine if this treatment can provide a safe and effective option for managing this condition in the long term.

The purpose of the study is to evaluate the effects of these treatments in patients who have not previously received treatment for CIDP. Participants will be randomly assigned to receive either Hizentra or Privigen. The study will last for a total of 26 weeks, during which the effects of the treatments on the participants’ symptoms will be monitored. This includes changes in their overall disability, muscle strength, and sensory function. The study will also assess the participants’ quality of life, pain levels, and satisfaction with the treatment.

Throughout the study, participants will undergo various tests to measure their progress. These tests include assessments of grip strength, walking ability, and other functional abilities. Blood samples will also be taken to monitor levels of immunoglobulin and other blood components. The study aims to determine which treatment is more effective in managing the symptoms of CIDP and improving the overall well-being of the participants.